Media stories about NeoGenomics (NASDAQ:NEO) have been trending somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NeoGenomics earned a news impact score of 0.17 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 46.3468085063088 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

NASDAQ:NEO opened at $9.17 on Tuesday. NeoGenomics has a 1-year low of $7.08 and a 1-year high of $11.63. The company has a current ratio of 2.42, a quick ratio of 2.21 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $683.51, a price-to-earnings ratio of 150.83, a P/E/G ratio of 4.72 and a beta of 0.42.

NeoGenomics (NASDAQ:NEO) last released its earnings results on Wednesday, February 21st. The medical research company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.02. NeoGenomics had a positive return on equity of 4.34% and a negative net margin of 1.37%. The firm had revenue of $67.79 million for the quarter, compared to analyst estimates of $66.32 million. During the same quarter in the prior year, the firm posted $0.05 earnings per share. The company’s quarterly revenue was up 12.1% on a year-over-year basis. research analysts anticipate that NeoGenomics will post 0.09 EPS for the current year.

Several equities analysts recently issued reports on the company. ValuEngine upgraded NeoGenomics from a “hold” rating to a “buy” rating in a report on Tuesday. BidaskClub raised NeoGenomics from a “sell” rating to a “hold” rating in a research note on Monday, February 5th. Royal Bank of Canada increased their target price on NeoGenomics from $23.00 to $24.00 and gave the company an “outperform” rating in a research note on Tuesday, March 13th. BTIG Research raised NeoGenomics from a “neutral” rating to an “outperform” rating in a research note on Monday. Finally, Scotiabank increased their target price on NeoGenomics from $22.00 to $23.00 and gave the company an “outperform” rating in a research note on Tuesday, March 13th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. NeoGenomics presently has a consensus rating of “Buy” and an average price target of $17.29.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.

Insider Buying and Selling by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with's FREE daily email newsletter.